In focus · trending topic

Orphan-Drug Designation

3 stories · following the connections

Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)

By Nasdaq OMXApr 9, 2018, 11:00 AM UTC

Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USA

By Nasdaq OMXJan 29, 2018, 12:00 PM UTC

Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)

By Nasdaq OMXDec 22, 2017, 1:00 PM UTC